QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.095109v1 316/2/892    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colpaert, F. C. Articles by Adriaensen, H. Search for Related Content PubMed PubMed Citation Articles by Colpaert, F. C. Articles by Adriaensen, H.

BEHAVIORAL PHARMACOLOGY

High-Efficacy 5-Hydroxytryptamine 1A Receptor Activation Counteracts Opioid Hyperallodynia and Affective Conditioning

Centre de Recherche Pierre Fabre, Castres, France (F.C.C.); Laboratory of Anesthesiology, University of Antwerp, Antwerp, Belgium (K.D., H.A.); and Centre National de la Recherche Scientifique, Université Victor Ségalen Bordeaux II, Bordeaux, France (L.S.)

Pain may become intractable as tolerance develops to opioids and the opioids, paradoxically, induce pain. We examined the hypothesis that the analgesia produced by the novel analgesic and high-efficacy 5-hydroxytryptamine (5-HT)_1A receptor agonist (3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]methyl}piperidin-1-yl]methanone, fumaric acid salt (F 13640) may counteract opioid-induced pain. In studies of the somatosensory quality of pain in infraorbital nerve-injured rats, morphine infusion (5 mg/day) by means of osmotic pumps initially caused analgesia (i.e., decreased the behavioral response to von Frey filament stimulation), followed by hyperallodynia and analgesic tolerance. Infusion of F 13640 (0.63 mg/day) prevented the development of opioid hyperallodynia and reversed opioid hyperallodynia once established. In studies of the affective/motivational quality of pain, F 13640 both prevented and reversed the conditioned place aversion induced by naloxone (0.04 mg/kg i.p.) in morphine-infused rats; F 13640 also prevented and reversed the conditioned place preference induced by morphine injections (7.5 mg/kg i.p.). The data confirm that opioids produce bidirectional hypo- and proalgesic actions, and offer initial evidence that high-efficacy 5-HT_1A receptor activation counteracts both the sensory and the affective/motivational qualities of opioid-induced pain. The data also indicate that F 13640 may be effective with opioid-resistant pain. It further is suggested that opioid addiction may represent self-therapy of opioid-induced pathological pain.

Address correspondence to: Dr. Francis Colpaert, Centre de Recherche Pierre Fabre, 17, avenue Jean Moulin, Castres, Cedex 06, F-81106, France. E-mail: francis.colpaert{at}pierre-fabre.com

This article has been cited by other articles:

				Z. D. Cooper, Y. N.-T. Truong, Y.-G. Shi, and J. H. Woods Morphine Deprivation Increases Self-Administration of the Fast- and Short-Acting {micro}-Opioid Receptor Agonist Remifentanil in the Rat J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 920 - 929. [Abstract] [Full Text] [PDF]

				M. Fallon and L. Colvin Opioid-induced hyperalgesia: fact or fiction? Palliative Medicine, January 1, 2008; 22(1): 5 - 6. [PDF]